Biomarker for Differentiating MS From NMOSD Identified in Study

Why It Matters

Accurate early differentiation of MS from NMOSD and MOGAD enables timely, disease‑specific therapy, reducing disability risk and health‑system costs.

Key Takeaways

• EBNA‑1 titers differentiate MS from NMOSD/MOGAD with ~95% accuracy
• MS patients maintain high EBNA‑1 levels over time
• Biomarker works across ages, sexes, and pediatric cases
• Study limited by retrospective design and gender imbalance

Pulse Analysis

The overlap of clinical symptoms and MRI findings among multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin‑oligodendrocyte glycoprotein antibody‑associated disease has long complicated early diagnosis. While cerebrospinal fluid oligoclonal bands and aquaporin‑4 antibodies provide disease‑specific clues, a single serological marker that reliably separates these entities has been elusive. Epstein‑Barr virus, particularly the nuclear antigen‑1 (EBNA‑1) protein, has been implicated in MS pathogenesis for decades, prompting investigators to explore whether quantitative EBNA‑1 antibody responses could serve as a diagnostic discriminator.

The multi‑center JAMA Neurology study measured EBNA‑1 peptide antibodies in 1,338 patients and demonstrated that persistent high‑titer responses were present in more than 96% of relapsing‑remitting MS cases, yet rare in MOGAD and NMOSD cohorts. By requiring elevated titers in at least two longitudinal samples, the assay achieved roughly 95% accuracy against MOGAD and 93% against NMOSD, independent of age, sex, or disease onset. Such performance suggests that EBNA‑1 serology could be incorporated into existing diagnostic pathways, offering a non‑invasive, cost‑effective adjunct to imaging and CSF analysis.

Despite its promise, the research design—retrospective case‑control with an imbalanced gender distribution—limits immediate clinical adoption. Prospective validation in diverse populations, alongside standardization of assay thresholds, will be essential before regulatory endorsement. If confirmed, the biomarker could accelerate initiation of disease‑modifying therapies tailored to each condition, reducing irreversible neurologic damage and associated health‑care expenditures. Moreover, the findings reinforce the broader hypothesis that chronic EBV infection contributes to autoimmunity, opening avenues for targeted antiviral strategies in multiple sclerosis and related demyelinating disorders.